Partner and Co-Head of North America Transactions
New York Office | pete.garrambone@torreya.com | 212.257.5808
Pete Garrambone, a Partner at Torreya, is Co-Head of North America Transactions Advisory. With 25 years of experience as a business development professional in the healthcare industry, he has led and completed more than 50 licensing and M&A transactions valued at over $250 billion.
Pete joined Torreya in 2008. Previously, he was a board member and interim CEO of Aegerion Pharmaceuticals, and Senior Vice President of Business Development at Reliant Pharmaceuticals.
Pete spent 24 years at Pfizer, where he served in several executive positions, including Vice President of Corporate Finance, Senior Vice President of Corporate Strategic Planning and Business Development, and Senior Vice President of the Medical Technology Group. While at Pfizer, Pete led numerous acquisitions and divestitures.
Notable transaction work prior to joining Torreya includes the sale of Reliant Pharmaceuticals to GlaxoSmithKline for $1.65 billion; Pfizer’s $117 billion acquisition of Warner-Lambert, $56 billion acquisition of Pharmacia, $1.3 billion acquisition of Esperion, and $1.9 billion acquisition of Vicuron; the divestiture of Pfizer’s consumer healthcare business to J&J for $16.6 billion; Pfizer’s divestiture of Schneider to Boston Scientific for $2.1 billion; and Pfizer’s divestiture of Howmedica to Stryker for $1.65 billion.
Pete graduated from Colby College with a B.A. in mathematics and economics, and holds an M.B.A. from The Tuck School of Business at Dartmouth.
![]() |
Sale of Intrathecal business to |
![]() |
$203 million
March 2017
|
![]() |
Sale to |
![]() |
$658 million
June 2014
|
![]() |
Sale to |
![]() |
$75 million upfront + milestones
May 2014
|
![]() |
Sale of Naprelan® to |
![]() |
Undisclosed
November 2013
|
![]() |
Advisor in the acquisition of six products from |
![]() |
Undisclosed
July 2010
|
![]() |
Sale to |
![]() |
Up to $34 million
November 2017
|
![]() |
Sale of Pessac plant to |
![]() |
Up to €22 million
November 2014
|
![]() |
Sale of substantially all assets to |
![]() |
Undisclosed
February 2014
|
![]() |
Divestiture of three pediatric drugs to |
![]() |
$28.7 million
May 2013
|
![]() |
Acquisition of EU rights to Vibativ® from |
![]() |
$5 million + royalties
March 2013
|
![]() |
Divestiture of Cuvposa® to |
![]() |
Undisclosed
August 2012
|
![]() |
Acquisition of |
![]() |
$40 million +
milestones June 2010
|